NICE announce planned timeline for assessing Vertex’s triple combination therapy (known as Trikafta in the US) and the EMA allow more time in their process to assess who the license would cover.
This morning the drug manufacturer Vertex announced some encouraging preliminary results for their next generation of precision medicine. But what does it all mean? We asked Dr Janet Allen, Director of Strategic Innovation at the Trust, to pull out the key findings from the press release.
The Trust’s Clinical Trials Accelerator Platform is growing its network of UK cystic fibrosis (CF) centres through a collaborative new scheme, expanding clinical trial accessibility for the CF community.
The James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF) is calling on the CF community to help them turn your research priorities into ideas for new clinical trials.
The Prime Minister’s Party Conference speech was splashed across the news for reasons Theresa May would rather forget but at Trust HQ, we were celebrating a major campaigning victory for people with cystic fibrosis – as Mrs May announced that the UK Government would be tackling the organ donor crisis head on. We asked Nick Medhurst, Head of Policy at the Trust, about the new opt-out legislation, and what it could mean for people with cystic fibrosis.
Meet this year’s CF’s Got Talent! winner Sara Cuevas Ocaña, who works on the Trust-funded Strategic Research Centre “INOVCF”, investigating non-CFTR approaches to CF therapies, and presented her research on stem cells to our online audience at this year's UK CF Conference.
